About Sienna Biopharmaceuticals (NASDAQ:SNNA)
Sienna Biopharmaceuticals, Inc. is a United States-based medical dermatology and aesthetics company. The Company focuses on developing targeted therapies to treat inflammatory skin conditions and aesthetic concerns that impact the health and appearance of patients. Its research and clinical-stage candidates include programs, such as SNA-001, SNA-120 and SNA-125. The Company has developed over 70 products. Its SNA-120 and SNA-125 are generated through its Topical by Design platform technology. Its SNA-120 is a Topical Tropomyosin Receptor Kinase A (TrkA) inhibitor for pruritus and psoriasis. Its SNA-125 is a Topical TrkA/Janus Kinase 3 (JAK3) Inhibitor for atopic dermatitis, psoriasis and pruritus. Its SNA-001 is a Topical Photoparticle Therapy for medical and aesthetic applications. Its SNA-001 Topical Photoparticle Therapy is used for localized and non-systemic treatment of acne. Its SNA-001 Topical Photoparticle Therapy is used for reduction of light-pigmented hair.
Industry, Sector and Symbol:
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Sector: Medical
- Symbol: NASDAQ:SNNA
- CUSIP: N/A
- Web: www.siennabio.com
- Current Ratio: 6.72%
- Quick Ratio: 6.72%
- Employees: 43
- Outstanding Shares: 20,540,000
Frequently Asked Questions for Sienna Biopharmaceuticals (NASDAQ:SNNA)
What is Sienna Biopharmaceuticals' stock symbol?
Sienna Biopharmaceuticals trades on the NASDAQ under the ticker symbol "SNNA."
How were Sienna Biopharmaceuticals' earnings last quarter?
Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) released its quarterly earnings data on Thursday, September, 7th. The company reported ($6.50) earnings per share for the quarter, missing the consensus estimate of ($0.68) by $5.82. View Sienna Biopharmaceuticals' Earnings History.
When will Sienna Biopharmaceuticals make its next earnings announcement?
Where is Sienna Biopharmaceuticals' stock going? Where will Sienna Biopharmaceuticals' stock price be in 2017?
3 Wall Street analysts have issued twelve-month price objectives for Sienna Biopharmaceuticals' stock. Their forecasts range from $28.00 to $50.00. On average, they anticipate Sienna Biopharmaceuticals' stock price to reach $36.00 in the next twelve months. View Analyst Ratings for Sienna Biopharmaceuticals.
Who are some of Sienna Biopharmaceuticals' key competitors?
Some companies that are related to Sienna Biopharmaceuticals include CytomX Therapeutics (CTMX), Raptor Pharmaceutical Corp (RPTP), La Jolla Pharmaceutical Company (LJPC), Five Prime Therapeutics (FPRX), Akebia Therapeutics (AKBA), Alder BioPharmaceuticals (ALDR), MacroGenics (MGNX), Aclaris Therapeutics (ACRS), Rhythm Pharmaceuticals (RYTM), Dova Pharmaceuticals (DOVA), Aduro Biotech (ADRO), PTC Therapeutics (PTCT), ZIOPHARM Oncology (ZIOP), Reata Pharmaceuticals (RETA), Deciphera Pharmaceuticals (DCPH), Cytokinetics, Incorporated (CYTK), G1 THERAPEUTICS (GTHX) and Vanda Pharmaceuticals (VNDA).
Who are Sienna Biopharmaceuticals' key executives?
Sienna Biopharmaceuticals' management team includes the folowing people:
- Frederick C. Beddingfield III, M.D., Ph.D., President, Chief Executive Officer, Director (Age 51)
- Richard D. Peterson, Chief Financial Officer (Age 49)
- Majed Kheir, Vice President - Operations
- Susan Lundeen, Vice President - Human Resources
- Robert More, Director
When did Sienna Biopharmaceuticals IPO?
(SNNA) raised $64 million in an initial public offering (IPO) on Thursday, July 27th 2017. The company issued 4,300,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and BMO Capital Markets served as the underwriters for the IPO.
Who owns Sienna Biopharmaceuticals stock?
Sienna Biopharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Victory Capital Management Inc. (2.23%), TimesSquare Capital Management LLC (1.88%), Alyeska Investment Group L.P. (0.25%), Citadel Advisors LLC (0.10%), Bank of New York Mellon Corp (0.06%) and California State Teachers Retirement System (0.04%). Company insiders that own Sienna Biopharmaceuticals stock include Dennis M Fenton, Keith R Leonard, Paul F Lizzul, Richard D Peterson and Timothy K Andrews. View Institutional Ownership Trends for Sienna Biopharmaceuticals.
Who bought Sienna Biopharmaceuticals stock? Who is buying Sienna Biopharmaceuticals stock?
Sienna Biopharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., TimesSquare Capital Management LLC, Alyeska Investment Group L.P., Citadel Advisors LLC, Bank of New York Mellon Corp and California State Teachers Retirement System. Company insiders that have bought Sienna Biopharmaceuticals stock in the last two years include Dennis M Fenton, Keith R Leonard, Paul F Lizzul, Richard D Peterson and Timothy K Andrews. View Insider Buying and Selling for Sienna Biopharmaceuticals.
How do I buy Sienna Biopharmaceuticals stock?
Shares of Sienna Biopharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sienna Biopharmaceuticals' stock price today?
One share of Sienna Biopharmaceuticals stock can currently be purchased for approximately $19.03.
How big of a company is Sienna Biopharmaceuticals?
Sienna Biopharmaceuticals has a market capitalization of $390.86 million. Sienna Biopharmaceuticals employs 43 workers across the globe.
How can I contact Sienna Biopharmaceuticals?
Sienna Biopharmaceuticals' mailing address is 30699 Russell Ranch Road Suite 140, Westlake Village CA, 91362. The company can be reached via phone at 818-629-2256 or via email at [email protected]
MarketBeat Community Rating for Sienna Biopharmaceuticals (NASDAQ SNNA)MarketBeat's community ratings are surveys of what our community members think about Sienna Biopharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Sienna Biopharmaceuticals (NASDAQ:SNNA) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 3 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$36.00 (89.17% upside)|
Consensus Price Target History for Sienna Biopharmaceuticals (NASDAQ:SNNA)
Analysts' Ratings History for Sienna Biopharmaceuticals (NASDAQ:SNNA)
(Data available from 11/19/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|8/21/2017||Cowen and Company||Initiated Coverage||Outperform||$50.00||High|
|8/21/2017||J P Morgan Chase & Co||Initiated Coverage||Overweight -> Overweight||$28.00||High|
|8/21/2017||BMO Capital Markets||Initiated Coverage||Outperform||$30.00||High|
Earnings History and Estimates Chart for Sienna Biopharmaceuticals (NASDAQ:SNNA)
Earnings History by Quarter for Sienna Biopharmaceuticals (NASDAQ SNNA)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|12/7/2017|| || || || || || || || |
Earnings Estimates for Sienna Biopharmaceuticals (NASDAQ:SNNA)
Current Year EPS Consensus Estimate: $-2.1 EPS
Next Year EPS Consensus Estimate: $-2.58 EPS
Dividend History for Sienna Biopharmaceuticals (NASDAQ:SNNA)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Sienna Biopharmaceuticals (NASDAQ SNNA)
Institutional Ownership Percentage: 23.33%
Insider Trades by Quarter for Sienna Biopharmaceuticals (NASDAQ SNNA)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/18/2017||Dennis M Fenton||Director||Buy||1,250||$22.96||$28,700.00|| |
|8/1/2017||Keith R Leonard||Director||Buy||16,700||$15.00||$250,500.00|| |
|8/1/2017||Paul F Lizzul||Insider||Buy||10,000||$15.00||$150,000.00|| |
|8/1/2017||Richard D Peterson||CFO||Buy||7,000||$15.00||$105,000.00|| |
|8/1/2017||Timothy K Andrews||General Counsel||Buy||15,000||$15.00||$225,000.00|| |
Latest Headlines for Sienna Biopharmaceuticals (NASDAQ SNNA)
Financials are not available for this stock.
Sienna Biopharmaceuticals (NASDAQ SNNA) Chart for Sunday, November, 19, 2017